Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1166) 1166
humans (1064) 1064
life sciences & biomedicine (1017) 1017
male (708) 708
cholesterol (583) 583
anticholesteremic agents - therapeutic use (573) 573
female (570) 570
anticholesteremic agents (567) 567
middle aged (472) 472
biological and medical sciences (397) 397
animals (376) 376
lipids (368) 368
medical sciences (354) 354
anticholesteremic agents - pharmacology (345) 345
adult (305) 305
aged (296) 296
statins (294) 294
cardiovascular disease (266) 266
abridged index medicus (264) 264
cholesterol, ldl - blood (249) 249
low density lipoproteins (243) 243
risk factors (226) 226
atherosclerosis (225) 225
hypercholesterolemia - drug therapy (213) 213
treatment outcome (196) 196
analysis (195) 195
hypercholesterolemia (187) 187
drug therapy (184) 184
cardiovascular system & cardiology (183) 183
anticholesteremic agents - administration & dosage (177) 177
research (174) 174
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (173) 173
lipoproteins (170) 170
cholesterol - blood (167) 167
general & internal medicine (167) 167
diabetes (165) 165
medicine, general & internal (165) 165
pharmacology & pharmacy (163) 163
immunology (159) 159
anticholesteremic agents - adverse effects (158) 158
cardiac & cardiovascular systems (158) 158
low density lipoprotein (149) 149
multidisciplinary sciences (149) 149
pharmacology. drug treatments (149) 149
science & technology - other topics (149) 149
atorvastatin calcium (147) 147
internal medicine (146) 146
medicine (142) 142
cardiovascular diseases (138) 138
research article (135) 135
mice (134) 134
medical research (130) 130
care and treatment (127) 127
science (121) 121
cardiovascular agents (120) 120
double-blind method (120) 120
ezetimibe (119) 119
physiological aspects (119) 119
clinical trials (118) 118
triglycerides (118) 118
health aspects (114) 114
inflammation (114) 114
hypercholesterolemia - blood (110) 110
proteins (110) 110
drug therapy, combination (108) 108
endocrinology & metabolism (103) 103
cardiovascular (102) 102
antilipemic agents (99) 99
atorvastatin (98) 98
coronary heart disease (96) 96
rats (95) 95
simvastatin (95) 95
cardiology (94) 94
rodents (94) 94
cardiology and cardiovascular medicine (92) 92
triglycerides - blood (92) 92
biochemistry & molecular biology (90) 90
cholesterol - metabolism (90) 90
metabolism (89) 89
patients (89) 89
biochemistry (88) 88
cell biology (88) 88
heptanoic acids - therapeutic use (88) 88
pyrroles - therapeutic use (88) 88
lipids - blood (87) 87
diet (86) 86
metabolic diseases (86) 86
diabetes mellitus (83) 83
cardiovascular diseases - prevention & control (82) 82
fundamental and applied biological sciences. psychology (82) 82
mortality (82) 82
cholesterol, hdl - blood (81) 81
studies (81) 81
blood cholesterol (80) 80
medicine, experimental (79) 79
cardiology. vascular system (76) 76
general and cellular metabolism. vitamins (76) 76
medicine & public health (76) 76
drugs (73) 73
type 2 diabetes (71) 71
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1502) 1502
German (8) 8
Japanese (6) 6
Spanish (5) 5
French (4) 4
Italian (2) 2
Portuguese (2) 2
Russian (2) 2
Danish (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
by Bays, Harold and Gaudet, Daniel and Weiss, Robert and Ruiz, Juan Lima and Watts, Gerald F and Gouni-Berthold, Ioanna and Robinson, Jennifer and Zhao, Jian and Hanotin, Corinne and Donahue, Stephen
The journal of clinical endocrinology and metabolism, ISSN 0021-972X, 08/2015, Volume 100, Issue 8, pp. 3140 - 3148
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Azetidines - immunology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Ezetimibe | Male | Heptanoic Acids - adverse effects | Pyrroles - immunology | Pyrroles - administration & dosage | Cardiovascular Diseases - blood | Heptanoic Acids - administration & dosage | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Drug Therapy, Combination | Antibodies, Monoclonal - immunology | Azetidines - adverse effects | Treatment Outcome | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Atorvastatin Calcium | Heptanoic Acids - immunology | Azetidines - administration & dosage | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Antibodies - blood | Aged | Index Medicus | Abridged Index Medicus | Original | 3 | 14
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
by Ridker, Paul M and Tardif, Jean-Claude and Amarenco, Pierre and Duggan, William and Glynn, Robert J and Jukema, J. Wouter and Kastelein, John J.P and Kim, Albert M and Koenig, Wolfgang and Nissen, Steven and Revkin, James and Rose, Lynda M and Santos, Raul D and Schwartz, Pamela F and Shear, Charles L and Yunis, Carla and SPIRE Investigators
The New England journal of medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1517 - 1526
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypercholesterolemia - immunology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Male | Treatment Outcome | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Proprotein Convertase 9 - blood | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Complications and side effects | Treatment outcome | Immune response | Patient outcomes | Analysis | Dosage and administration | Antilipemic agents | Lipoproteins (low density) | Hyperlipidemia | Clinical trials | Lipids | Subtilisin | Patients | Low density lipoprotein | Cholesterol | Studies | Apolipoprotein B | Kexin | Monoclonal antibodies | Statins | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9
by Chaparro-Riggers, Javier and Liang, Hong and DeVay, Rachel M and Bai, Lanfang and Sutton, Janette E and Chen, Wei and Geng, Tao and Lindquist, Kevin and Casas, Meritxell Galindo and Boustany, Leila M and Brown, Colleen L and Chabot, Jeffrey and Gomes, Bruce and Garzone, Pamela and Rossi, Andrea and Strop, Pavel and Shelton, Dave and Pons, Jaume and Rajpal, Arvind
The Journal of biological chemistry, ISSN 0021-9258, 03/2012, Volume 287, Issue 14, pp. 11090 - 11097
Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Anticholesteremic Agents - blood | Humans | Receptors, Fc - metabolism | Half-Life | Macaca fascicularis | Male | Proprotein Convertases - immunology | Anticholesteremic Agents - immunology | Hep G2 Cells | Anticholesteremic Agents - pharmacokinetics | Animals | Lysosomes - metabolism | Antibodies, Monoclonal, Humanized - pharmacokinetics | Complementarity Determining Regions - chemistry | Antibodies, Monoclonal, Humanized - blood | Antibodies, Monoclonal, Humanized - pharmacology | Protein Engineering | Serine Endopeptidases - immunology | Mice | Antibodies, Monoclonal, Humanized - immunology | Anticholesteremic Agents - pharmacology | Hydrogen-Ion Concentration | Proprotein Convertase 9 | Index Medicus | Cardiovascular Disease | Antibody Engineering | Pharmacodynamics | Immunology | Hypercholesterolemia | PCSK9 | Pharmacokinetics | Protein Degradation | Target-mediated Clearance | Antigen-mediated Clearance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis
by del Rincón, Inmaculada and Polak, Joseph F and O'Leary, Daniel H and Battafarano, Daniel F and Erikson, John M and Restrepo, Jose F and Molina, Emily and Escalante, Agustín
Annals of the rheumatic diseases, ISSN 0003-4967, 06/2015, Volume 74, Issue 6, pp. 1118 - 1123
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Blood Sedimentation | Humans | Middle Aged | Hypertension - drug therapy | Male | Atherosclerosis - epidemiology | Hypercholesterolemia - drug therapy | Atherosclerosis - diagnostic imaging | Carotid Artery Diseases - diagnostic imaging | Arthritis, Rheumatoid - drug therapy | Cardiovascular Diseases - diagnostic imaging | Cardiovascular Diseases - epidemiology | Female | Hypertension - epidemiology | Antirheumatic Agents - therapeutic use | Hypercholesterolemia - epidemiology | Hypoglycemic Agents - therapeutic use | Hypercholesterolemia - blood | Atherosclerosis - immunology | HLA-DRB1 Chains - genetics | Carotid Intima-Media Thickness | Risk Factors | Diabetes Mellitus - drug therapy | Peptides, Cyclic - immunology | Inflammation - immunology | Antihypertensive Agents - therapeutic use | Disease Progression | Cardiovascular Diseases - immunology | Rheumatoid Factor - immunology | Arthritis, Rheumatoid - genetics | Anticholesteremic Agents - therapeutic use | Carotid Arteries - diagnostic imaging | Smoking - epidemiology | Diabetes Mellitus - epidemiology | Obesity - epidemiology | Aged | Arthritis, Rheumatoid - immunology | Longitudinal Studies | Hypertension | Studies | Variables | Obesity | Reading | Ultrasonic imaging | Laboratories | Atherosclerosis | Inflammation | Diabetes | Carotid arteries | Veins & arteries | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
by Ridker, Paul M and Revkin, James and Amarenco, Pierre and Brunell, Robert and Curto, Madelyn and Civeira, Fernando and Flather, Marcus and Glynn, Robert J and Gregoire, Jean and Jukema, J. Wouter and Karpov, Yuri and Kastelein, John J.P and Koenig, Wolfgang and Lorenzatti, Alberto and Manga, Pravin and Masiukiewicz, Urszula and Miller, Michael and Mosterd, Arend and Murin, Jan and Nicolau, Jose C and Nissen, Steven and Ponikowski, Piotr and Santos, Raul D and Schwartz, Pamela F and Soran, Handrean and White, Harvey and Wright, R. Scott and Vrablik, Michal and Yunis, Carla and Shear, Charles L and Tardif, Jean-Claude and SPIRE Cardiovascular Outcome Inve and ICON and Miller Tanner Associates and Julius Clinical and Acurian and C5 and ICON Analytical Lab and Boston Clinical Res Inst and IMI and COVANCE and SPIRE Cardiovascular Outcome Investigators
The New England journal of medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Treatment Failure | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Immunoglobulins | Stroke | Risk groups | Clinical trials | Cardiovascular disease | Lipids | Subtilisin | Angina | Low density lipoprotein | Manuscripts | Cholesterol | Disease prevention | Kexin | Monoclonal antibodies | Cardiovascular diseases | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells
by Hot, Arnaud and Lavocat, Fabien and Lenief, Vanina and Miossec, Pierre
Annals of the rheumatic diseases, ISSN 0003-4967, 05/2013, Volume 72, Issue 5, pp. 754 - 760
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Human Umbilical Vein Endothelial Cells | Interleukin-8 - genetics | Gene Expression - drug effects | Humans | Interleukin-17 - immunology | Interleukin-17 - pharmacology | Simvastatin - pharmacology | Drug Interactions | Infliximab | Gene Expression - immunology | Tumor Necrosis Factor-alpha - immunology | Platelet Aggregation - drug effects | Antirheumatic Agents - pharmacology | Thrombosis - prevention & control | Atherosclerosis - drug therapy | Atherosclerosis - immunology | Interleukin-6 - genetics | Platelet Aggregation - immunology | Anti-Inflammatory Agents - pharmacology | Antibodies, Monoclonal - pharmacology | Thrombosis - immunology | Endothelial Cells - immunology | Tumor Necrosis Factor-alpha - pharmacology | Endothelial Cells - cytology | Interleukin-6 - immunology | Thrombosis - drug therapy | Interleukin-8 - immunology | Anticholesteremic Agents - pharmacology | Atherosclerosis - prevention & control | Endothelial Cells - drug effects | Care and treatment | Interleukins | Tumor necrosis factor | Simvastatin | Atherosclerosis | Influence | Research | Endothelium | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation
by Coimbra, Maria and Banciu, Manuela and Fens, Marcel H.A.M and de Smet, Lieselotte and Cabaj, Magda and Metselaar, Josbert M and Storm, Gert and Schiffelers, Raymond M
Journal of controlled release, ISSN 0168-3659, 2010, Volume 148, Issue 3, pp. 303 - 310
Liposome | MHC class I | Angiogenesis | Inflammation | Statin | Cancer | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Pharmaceutical technology. Pharmaceutical industry | Biological and medical sciences | Medical sciences | General pharmacology | Pharmacology. Drug treatments | Genes, MHC Class I - drug effects | Humans | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasms - complications | Neoplasms - genetics | Inflammation - drug therapy | Angiogenic Proteins - immunology | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Pravastatin - therapeutic use | Cytokines - immunology | Pravastatin - pharmacology | Cell Survival - drug effects | Anti-Inflammatory Agents - pharmacology | Mice, Inbred C57BL | Inflammation - etiology | Neoplasms - drug therapy | Anticholesteremic Agents - pharmacokinetics | Animals | Anticholesteremic Agents - therapeutic use | Pravastatin - administration & dosage | Neoplasms - immunology | Anticholesteremic Agents - administration & dosage | Lipid Metabolism - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Liposomes | Anticholesteremic Agents - pharmacology | Pravastatin - pharmacokinetics | Proteins | Post-translational modification | Cell research | Care and treatment | Growth | Physiological aspects | Pravastatin | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
by Giugliano, Robert P, Dr and Desai, Nihar R, MD and Kohli, Payal, MD and Rogers, William J, Prof and Somaratne, Ransi, MD and Huang, Fannie, MS and Liu, Thomas, PhD and Mohanavelu, Satishkumar, MS and Hoffman, Elaine B, PhD and McDonald, Shannon T, BSN and Abrahamsen, Timothy E, BA and Wasserman, Scott M, MD and Scott, Robert, MD and Sabatine, Marc S, MD and for the LAPLACE-TIMI 57 Investigators and LAPLACE-TIMI 57 Investigators
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9858, pp. 2007 - 2017
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | Metabolic diseases | General aspects | Medical sciences | Disorders of blood lipids. Hyperlipoproteinemia | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Ezetimibe | Male | Hypercholesterolemia - drug therapy | Dose-Response Relationship, Drug | Young Adult | Immunoglobulin G - immunology | Serine Endopeptidases - immunology | Aged, 80 and over | Adult | Cholesterol, LDL - blood | Female | Drug Therapy, Combination | Double-Blind Method | Azetidines - adverse effects | Treatment Outcome | Anticholesteremic Agents - adverse effects | Proprotein Convertases - immunology | Azetidines - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Analysis of Variance | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Cholesterol, HDL - blood | Aged | Proprotein Convertase 9 | Monoclonal antibodies | Usage | Hypercholesterolemia | Research | Drug therapy | Clinical trials | Cardiovascular disease | Apolipoproteins | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients
by Overton, Edgar Turner and Sterrett, Sarah and Westfall, Andrew O and Kahan, Shannon M and Burkholder, Greer and Zajac, Allan J and Goepfert, Paul A and Bansal, Anju
AIDS (London), ISSN 0269-9370, 2014, Volume 28, Issue 17, pp. 2627 - 2631
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | T-Lymphocyte Subsets - immunology | Anti-Retroviral Agents - therapeutic use | HIV Infections - virology | Heptanoic Acids - therapeutic use | Humans | Interferon-gamma - secretion | Atorvastatin Calcium | HIV Infections - immunology | HIV-1 - immunology | Anticholesteremic Agents - therapeutic use | Lymphocyte Activation - drug effects | T-Lymphocytes - drug effects | T-Lymphocytes - immunology | Retrospective Studies | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Immunologic Factors - therapeutic use | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
by Stein, Evan A and Mellis, Scott and Yancopoulos, George D and Stahl, Neil and Logan, Douglas and Smith, William B and Lisbon, Eleanor and Gutierrez, Maria and Webb, Cheryle and Wu, Richard and Du, Yunling and Kranz, Therese and Gasparino, Evelyn and Swergold, Gary D
The New England journal of medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 12, pp. 1108 - 1118
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Proprotein Convertases - antagonists & inhibitors | Injections, Intravenous | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Hypercholesterolemia - drug therapy | Dose-Response Relationship, Drug | Injections, Subcutaneous | Serine Endopeptidases - immunology | Adult | Cholesterol, LDL - blood | Female | Hyperlipoproteinemia Type II - drug therapy | Drug Therapy, Combination | Pyrroles - therapeutic use | Proprotein Convertases - metabolism | Receptors, LDL - metabolism | Lipoproteins - blood | Anticholesteremic Agents - adverse effects | Proprotein Convertases - immunology | Hyperlipoproteinemia Type II - metabolism | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Least-Squares Analysis | Serine Endopeptidases - metabolism | Receptors, LDL - drug effects | Hypercholesterolemia - metabolism | Proprotein Convertase 9 | Drugs | Dose-response relationship (Biochemistry) | Hypercholesterolemia | Monoclonal antibodies | Cholesterol, LDL | Dosage and administration | Product/Service Evaluations | Research | Drug therapy | Health aspects | Studies | Lipoproteins (low density) | Kexin | Serine | Atorvastatin | Cardiovascular disease | Subtilisin | Low density lipoprotein | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights